The real-world practice for patients with atopic dermatitis who developed ocular surface disease under treatment with dupilumab: A post-hoc analysis from two-year post-marketing surveillance in Japan

Allergology International · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles